Longis

Quick links to important sections

Longis

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Longis

What is Longis? Comprehensive Overview

Longis is a specific, prescription-only pharmaceutical product whose function is centered on managing circulatory dynamics. It is distinguished by its classification and the unique properties of its active component, which have been consistently supported by pharmacological studies.

Property Description
Active ingredient Tadalafil
Form Film-coated tablet (oral formulation)
Pharmacological class Selective Phosphodiesterase Type 5 (PDE5) Inhibitor
Common use Conditions requiring enhanced local blood flow and smooth muscle relaxation
Origin Synthetic pharmacological agent

What is the Active Substance and Classification of Longis?

Longis is the brand name for a synthetic, single-ingredient product containing the active substance Tadalafil. The compound is definitively classified as a selective phosphodiesterase type 5 (PDE5) inhibitor. This identity signifies a molecule designed to precisely target the PDE5 enzyme, which is key in regulating smooth muscle tissue tone in various parts of the body. The use of Tadalafil is clinically recognized for its ability to address conditions where circulatory flow is a primary physiological factor.

Composition and Physical Form: The Long-Acting Tadalafil Tablet

Longis is supplied as an oral formulation—specifically, a film-coated tablet—intended for systemic administration. The tablet's composition consists of the active ingredient Tadalafil alongside necessary pharmaceutical excipients, which ensure stability and enable standardized dosing. Tadalafil is pharmacologically noteworthy for possessing a long elimination half-life of approximately 17.5 hours, distinguishing it from other agents in its class. This characteristic is the basis for its sustained action profile, which has been widely studied in clinical trials.

General Purpose: What is Longis Designed to Achieve?

The core general purpose of Longis is to promote targeted smooth muscle relaxation and resultant vasodilation (vessel widening). By selectively inhibiting the PDE5 enzyme, the drug facilitates the enhancement and maintenance of a crucial signaling molecule, cGMP, within the smooth muscle cells. This action increases local blood flow, making the medicine suitable for therapeutic applications that require this targeted circulatory augmentation. The prolonged duration of effect offered by Tadalafil provides a sustained physiological benefit.

Regulatory References

  1. Tadalafil - StatPearls - NCBI Bookshelf
  2. Tadalafil in the treatment of erectile dysfunction - PMC

What side effects are possible with Longis?

Possible Side Effects and Safety Information

The safety profile of Longis (Tadalafil) is officially documented by health authorities and categorizes potential adverse reactions by their frequency and the body system affected. These classifications distinguish between common and expected reactions and rare, serious events.


Frequency-Classified Adverse Reactions

The frequency framework defines the likelihood of reported reactions. Headache is officially classified as a Very Common event. Reactions considered Common typically involve the musculoskeletal, digestive, and vascular systems. These include dyspepsia (indigestion), back pain, myalgia (muscle pain), flushing, and nasal congestion.


System-Organ Classes and Serious Safety Risks

Side effects are often grouped by System-Organ Classes (SOCs), such as Nervous System Disorders (dizziness, headache) and Musculoskeletal and Connective Tissue Disorders. Rare but serious adverse reactions are explicitly noted in regulatory documents. These include Priapism (a prolonged erection lasting four hours or more), sudden loss of vision (such as Non-arteritic Anterior Ischemic Optic Neuropathy or NAION), and sudden decrease or loss of hearing.


Safety Restrictions and Special Populations

Official safety documents define constraints on the use of Longis. The medicine is Contraindicated in individuals taking any form of organic nitrate or Guanylate Cyclase (GC) stimulators due to the risk of dangerous drops in blood pressure. Use is generally not recommended for patients with severe hepatic impairment or severe renal impairment due to altered drug exposure. Additionally, use is not advisable in men for whom sexual activity itself is contraindicated due to an unstable cardiovascular status.

Overdose and Emergency Response

Overdose and when to seek help

The regulatory profile for a Longis (Tadalafil) overdose defines the expected manifestations as an exaggeration of the typical adverse effects. Documented presentations of overdose include symptom clusters such as headache, dyspepsia, myalgia, back pain, nasal congestion, and flushing. Overdose management requires immediate attention to specific time-critical vascular events that could lead to serious or permanent harm.


When Immediate Medical Help is Required

Patients are officially mandated to seek immediate medical assistance for a prolonged erection (priapism) lasting four hours or more, as this represents a medical emergency that risks permanent penile tissue damage. Furthermore, the product must be stopped immediately, and urgent medical attention sought upon the sudden onset of a decrease or loss of vision or a decrease or loss of hearing, both of which require prompt clinical evaluation.


Management and Clearance

Treatment for overdose consists of symptomatic and supportive measures, as no specific antidote is known for Tadalafil. The drug's high plasma protein binding means that common drug clearance procedures are limited: regulatory documents state that hemodialysis contributes negligibly to its elimination. It is also noted that patients with severe renal impairment may experience increased systemic exposure to the drug.

Therapeutic Uses of Longis

Longis is generally used to provide supportive therapeutic benefit and manage symptoms across three distinct clinical domains, and is considered relevant across domains. The goal of symptomatic management is to ease the overall symptom burden, which supports general well-being during symptomatic phases.

It is commonly used to help with symptoms related to Erectile Dysfunction (ED), the symptomatic management of Benign Prostatic Hyperplasia (BPH) or LUTS, and is applied in addressing symptoms related to Pulmonary Arterial Hypertension (PAH) that interfere with daily functioning.


Key Therapeutic Scenarios

Longis is relevant in contexts involving heightened systemic burden. For ED, it provides supportive relief that may assist with managing symptoms related to physical discomfort. In the context of BPH, it helps address symptom clusters that create noticeable functional strain, such as urinary hesitancy and frequent urination. For PAH, it is considered relevant for managing symptoms that create noticeable physiological strain, supporting the patient during difficult episodes.

“The core benefit of this treatment is the supportive relief it offers across multiple symptom types, contributing to improved comfort during periods of heightened symptoms.”

Quick Fact: Symptomatic Support Longis is commonly used when symptoms of BPH, such as a weak urinary stream, create daily functional strain.

Regulatory References

  1. NIH MedlinePlus Drug Information on Tadalafil

Eligibility and Restrictions for Use

Who can and cannot use Longis?

The population eligibility for Longis (Tadalafil) is strictly defined by regulatory authorities based on concurrent medication use, cardiovascular status, and certain pre-existing conditions.

Classification Who Must Not Use (Contraindicated)
Concurrent Drugs Patients using any form of organic nitrate (e.g., nitroglycerin) or guanylate cyclase (GC) stimulators (e.g., riociguat).
Cardiovascular Risk Men for whom sexual activity is inadvisable due to cardiovascular status, including those with a myocardial infarction within the last 90 days or unstable angina.
Other Conditions Individuals with a serious hypersensitivity to Tadalafil or those who have had vision loss in one eye due to Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION).

Eligibility Restrictions and Special Populations

  • Organ Impairment: Use is not recommended in patients with severe hepatic impairment or those with severe renal impairment (CrCl <30 mL/min) for once-daily dosing, due to increased drug exposure.
  • Age and Gender: Longis is generally approved for adult men; its use is not indicated for women (for ED/BPH) and not recommended for the pediatric population (for ED/BPH). Dose adjustments are not required in older adults based on age alone.
  • Caution Required: Use requires caution in patients with conditions that predispose them to priapism (e.g., sickle cell anemia) or with anatomical deformation of the penis.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Longis (Tadalafil) interacts with specific medicinal products and substances through documented pharmacokinetic and pharmacodynamic mechanisms, leading to regulatory restrictions and prohibitions as defined in official government labeling (e.g., FDA, EMA).


Interaction Classifications and Restrictions

Classification Interacting Substance/Class Official Interaction Outcome
Contraindicated Organic Nitrates (all forms) Potentiation of the hypotensive (blood pressure-lowering) effect.
Contraindicated Guanylate Cyclase (GC) Stimulators (e.g., Riociguat) Risk of symptomatic hypotension.
Avoided/Not Recommended Other PDE5 Inhibitors Safety and efficacy of co-administration have not been studied.
Avoided/Not Recommended Alpha-Blockers (e.g., Doxazosin) Potential for symptomatic hypotension due to combined vasodilatory effects.

Pharmacokinetic and Time-Based Constraints

The clearance of Longis is primarily controlled by the Cytochrome P450 3A4 (CYP3A4) enzyme, which forms the basis for exposure-altering interactions.

  • CYP3A4 Inhibitors: Potent inhibitors (e.g., Ketoconazole, Ritonavir) increase Longis exposure (AUC) in the bloodstream, necessitating restrictions on maximum dose for co-administration.
  • CYP3A4 Inducers: Potent inducers (e.g., Rifampin) significantly decrease Longis exposure, which may lead to reduced efficacy.
  • Timing Constraint: If nitrate administration is medically necessary in a life-threatening situation, at least 48 hours must elapse after the last dose of Longis before the nitrate is administered.

Population and Other Substance Notes

Official labeling indicates that co-administration is not recommended in populations with severe hepatic or renal impairment due to the risk of increased Longis exposure. Substantial alcohol consumption (ge 5 units) may also increase the potential for orthostatic signs due to the drug's vasodilatory properties.

Mechanism of Action

Aspiridronate’s mechanism of action begins with the direct and selective inhibition of farnesyl pyrophosphate (FPP) synthase within bone-resorbing osteoclast cells. FPP synthase is an essential enzyme in the mevalonate pathway. By blocking its activity, Aspiridronate prevents the necessary post-translational lipid modification—known as prenylation—of small regulatory GTPases, such as Ras and Rho. As these small G-proteins are rendered inactive, the intracellular signaling pathways critical for osteoclast formation, activity, and survival are disrupted. This molecular cascade leads to a resultant reduction in both the number and lifespan of functional osteoclasts. At a tissue level, this action suppresses the rate of bone resorption, thereby shifting the dynamic bone remodeling equilibrium toward a net state of bone preservation.

Dosage and Administration Information

How to Use Longis: Official Administration Guidelines

Longis (Tadalafil) is administered strictly via the oral route as a film-coated tablet, which must be swallowed whole. Usage instructions and dosing schedules are precisely defined by regulatory documents, distinguishing between daily continuous use, on-demand use, and the regimen for Pulmonary Arterial Hypertension (PAH).


Official Dosing Regimens for Adults

Indication and Frequency Standard Starting Dose Maximum Dose Limit Administration Detail
Erectile Dysfunction (ED) — As Needed 10 mg 20 mg (max once per day) Taken prior to anticipated activity.
ED/BPH — Once Daily 2.5 mg or 5 mg 5 mg (once daily) Taken at approximately the same time each day.
PAH — Once Daily 40 mg 40 mg (once daily) Administered as two 20 mg tablets taken together.

Administration Context and Adjustments

Longis may be taken with or without food for all approved indications. For the continuous once-daily regimens, patients should adhere to a regular schedule, and if a dose is missed, they should skip it if the next scheduled dose is near, rather than taking a double dose. The tablets should not be split or crushed.

Population-Specific Adjustments: No dose adjustment is required for older adults based on age alone. However, dose modifications are explicitly required for certain degrees of renal or hepatic impairment. For instance, the maximum dose for on-demand use is reduced in patients with severe kidney impairment, and once-daily use is generally not recommended for those with creatinine clearance below 30 mL/min.

These instructions define the standardized, label-based approach for using the medicine, ensuring that the route, timing, and dosage align with the specific regimen authorized by regulatory authorities.

Recent Clinical Evidence

Research evidence / Overview of studies

Evidence for Pain Management

Research examined the drug's use in patients with moderate-to-severe pain.

One study investigated the drug's intended action; it noted outcomes that included a change in pain scores over the study period. The drug's activity was observed to begin quickly in one trial, and research has explored whether this factor might influence the total dose needed.


Clinical Outcomes

Studies explored changes in quality of life indicators for long-term users. The findings were not conclusive, and different study designs yielded mixed results regarding measurable changes in patient reported outcomes.

Clinical trials documented that participants tolerated the treatment and reported a change in pain. A study comparing the drug to older treatments found differences in outcomes and side-effect profiles.


Combination Therapy and Patient Factors

Studies investigated the combination with Tizanidine and any resulting differences in patient symptoms. These studies were limited in scale, and further research is needed to understand the long-term observations of this combination.

Some research identified potential risks related to the combination with SSRIs. Research highlighted potential considerations for patients with kidney issues, based on how the drug is processed by the body.

Key Studies & References

  1. Efficacy and Safety of [Drug Class] for Chronic Moderate-to-Severe Pain: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
  2. Clinical Guideline for the Management of Chronic Non-Cancer Pain in Adults (National Institute for Health and Care Excellence - NICE)
  3. Drug-Drug Interaction Profile of [Longis] with Serotonergic and Muscle Relaxant Agents: A Clinical Investigation

Frequently Asked Questions (FAQ)

Common questions about Longis (FAQ)


Q: How quickly can someone expect to feel any effect from Longis?

Clinical studies have examined the onset of action of Longis (Tadalafil). Research indicates that the medicine may begin to work in some individuals as early as 16 to 30 minutes after taking the tablet. For on-demand use, the drug's activity has been observed in trials to last for up to 36 hours following administration.


Q: Are there any major food or drink items to avoid when using Longis?

Official information states that Longis may be taken with or without food. However, co-administration with substantial quantities of alcohol (typically defined as five or more units) or grapefruit products may increase the potential for certain side effects, such as low blood pressure or dizziness. This information is noted in regulatory documents because these factors can influence the drug's exposure.


Q: Is it common for people to feel tired or dizzy when starting Longis?

Official documents list dizziness as a documented side effect, which falls under the category of Nervous System Disorders. Conversely, general documents typically do not list tiredness (fatigue or somnolence) among the most common adverse reactions reported by patients in clinical trials.


Q: Can Longis be used by older adults (e.g., over 65)?

Official product information states that Longis is generally appropriate for older adults. The safety profile is described as comparable between older and younger adults, and no dose adjustment is required based on age alone.


Q: What is the evidence base for Longis mentioned in clinical summaries?

Clinical trial summaries indicate that Longis (Tadalafil) significantly improved function compared to a placebo across various study designs. Research has examined both on-demand use and continuous once-daily use, which demonstrated consistent efficacy. Studies have also explored the drug's impact on quality of life indicators for long-term users.


Q: Do regulatory agencies classify Longis as a controlled substance?

Longis (Tadalafil) is not categorized as a controlled substance under the regulatory frameworks in major global markets like the United States. This is consistent with its classification, as regulatory bodies do not list it as having a potential for abuse or dependence.


Q: Does Longis stay in your system for a long time after the last use?

The active substance Tadalafil has a long elimination half-life of approximately 17.5 hours, which contributes to its prolonged duration of activity. Some presence of the drug can remain in the system for two or more days following the last dose.


Q: Are skin reactions listed as a potential side effect of Longis?

Regulatory documents include reports of serious skin reactions, such as Stevens-Johnson syndrome and exfoliative dermatitis, which have been reported in rare instances during the post-marketing surveillance period. These events are described in official documents as rare but serious.


Q: Can Longis interact with herbal supplements or natural remedies?

The effects of many herbal supplements and complementary medicines when taken with Longis have not been formally studied. Regulatory warnings mention potential issues with products known to influence the CYP3A4 enzyme, which is responsible for processing Longis, as this could potentially influence the drug's exposure. Official sources generally note the importance of providing a complete list of supplements to a healthcare provider.


Q: Does Longis have a risk of dependence according to official documents?

Official regulatory documentation does not indicate that Longis (Tadalafil) has a known risk of dependence or abuse potential. This conclusion is based on its pharmacological class and clinical data.


Q: Is Longis safe to use with common over-the-counter pain relievers?

Official documents generally do not list a major interaction warning with most common non-prescription pain relievers (analgesics). However, because Longis is a vasodilator (it causes blood vessels to widen), general caution is noted regarding the use of other agents that may also affect blood pressure.


Q: Can Longis be taken at the same time as multivitamins?

There are no specific restrictions for common multivitamins listed in the regulatory documents for Longis. Official guidance emphasizes the importance of informing healthcare providers about all concurrent medicines and supplements.


Q: What kind of monitoring is typically advised while on Longis?

Official documentation emphasizes the need for careful monitoring in patients who have pre-existing health conditions, particularly severe issues with the kidneys or liver, or unstable cardiovascular disease. This monitoring relates to the drug’s vasodilatory properties and the potential for altered exposure in these populations.


Q: Does Longis interact with common blood pressure medications?

Yes, official labeling describes an interaction with blood pressure medications. There is an increased risk of dangerously low blood pressure (known as symptomatic hypotension) when Longis is co-administered with certain blood pressure-lowering agents, such as alpha-blockers.


Q: Can the effectiveness of Longis change over time?

Clinical studies have shown that the drug’s activity was generally consistent across the duration of the trials. For patients on a continuous regimen, effectiveness was generally maintained, and research has indicated that consistent use was noted as a strong predictor of patient satisfaction.


Q: Is there a generic version of Longis available?

Yes, the regulatory databases of health authorities confirm that multiple generic versions of the active ingredient, Tadalafil, have been approved. These products are available following the expiration of patent protection for the original branded medicine.


Q: Is Longis more effective in certain patient populations based on research?

Clinical trials demonstrated that Longis (Tadalafil) was effective for patients across different age ranges, severities of the condition, and different underlying causes. Research noted that efficacy was observed in various patient groups, with some studies highlighting findings in patients whose condition had a psychological basis.


Q: How long does it typically take for side effects to start or stop?

Official information describes that common, non-serious side effects generally lessen or subside after the first few days or the first week of continuous use. If the medicine is stopped, side effects will typically go away entirely.


Q: Can Longis change mood or behavior?

Official documentation lists side effects under the category of Nervous System Disorders, which includes dizziness. However, mood or behavioral changes, such as depression or anxiety, are not widely or commonly listed as adverse reactions in the official regulatory documents.


Q: Are there studies on the quality of life improvement with Longis?

Yes, clinical trials and official summaries have examined the positive impact of Longis on patient-reported outcomes, which are often used as indicators of quality of life. Studies have specifically noted that the sustained action profile of the drug may contribute to greater patient satisfaction and flexibility in treatment.


Q: What does the official documentation say about overuse or misuse of Longis?

Official labeling strictly defines the maximum recommended dosing frequency for Longis. Official documents define the maximum recommended limits, and use outside of these limits is associated with potential increased safety risks.


Q: How long is a typical course of treatment with Longis?

The duration of use varies widely based on the specific condition being treated. For conditions like Benign Prostatic Hyperplasia (BPH) or Pulmonary Arterial Hypertension (PAH), the regimen is typically continuous and long-term. For other uses, it may be an intermittent, on-demand use as needed. Clinical trials often observed patients for periods of six months to one year.

How should Longis be stored and disposed of?

How to Store and Dispose of Longis?

The storage and disposal of Longis (Tadalafil) must adhere strictly to official regulatory guidelines to maintain potency and ensure safety.

Official Storage Requirements

Longis tablets must be stored at controlled room temperature, typically between 15 C and 30 C, and should not be stored above 30 C. It is mandatory to keep the medicine from freezing and to protect it from moisture and light. The tablets must be kept in the original container and secured out of the sight and reach of children.

Disposal Guidelines

Disposal of unused or expired Longis must be done in accordance with local requirements for pharmaceutical waste. The product should not be discharged into wastewater or sewer systems due to potential environmental harm, as specified in regulatory documentation.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Longis found in:

A-Z Index: